Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-line<i>Helicobacter pylori</i>eradication: a prospective randomised study

Chen, L.-W.; Chien, Rong Nan; Chang, Jia-Jang; Fang, Kuan-Meen; Chang, Liang‐Che

doi:10.1111/j.1742-1241.2010.02482.x

Cited by 15 publications

(13 citation statements)

References 23 publications

(52 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Chen et al (35) emphasized that efficacy and tolerability of once-daily and twice-daily triple therapy (levofloxacin 500 mg, esomeprazole 40 mg and clarithromycin 500 mg) were equal; however, none of the regimens was effective enough to be considered as a recommendable first-line treatment.…”

Section: Discussionmentioning

confidence: 99%

Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin

Seven¹,

Çınar²,

Yakut³

et al. 2011

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin

Seven¹,

Çınar²,

Yakut³

et al. 2011

Turk J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…However, with the rapid increase of antibiotic resistance, the most commonly recommended regimen led to an unacceptably low success rate for the treatment (Table .). Zheng et al.…”

Section: Eradication Of H Pylori Infectionmentioning

confidence: 99%

Review: Clinical Management of Helicobacter pylori Infection in China

Xie

Lü

2014

Helicobacter

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) infection has been associated with gastric disorders. The situation of H. pylori infection in China-where a high prevalence of H. pylori infection, a high incidence of gastric cancer, and widespread resistance to clarithromycin, metronidazole, and levofloxacin exist-is quite different from that in Western countries. In order for Chinese clinicians to better manage H. pylori infection, a Chinese Study Group on H. pylori published four consensus reports regarding the management of H. pylori infection in China between 1999 and 2012. The eradication rate with standard triple therapy was <80% in most areas of China. Bismuth is available in China, and bismuth-containing quadruple therapy has been shown to produce a high eradication rate; thus, bismuth quadruple therapy could be recommended both as an initial and as a rescue therapy in China. There is no advantage of sequential therapy over triple therapy in Chinese patients, but the efficacy of concomitant therapy must be studied further. This review introduces the epidemiology, diagnosis, indicators, and therapies for the eradication of H. pylori in China in recent years.

show abstract

“…Studies demonstrated that increasing the dosage of levofloxacin cannot overcome levofloxacin resistance [38, 39]. Furthermore, previous studies suggest that once-daily dosing of a levofloxacin-based triple regimen may be as efficacious as twice daily [40]. …”

Section: Quinolone-based Therapymentioning

confidence: 99%

The Optimal First-Line Therapy ofHelicobacter pyloriInfection in Year 2012

Kuo

et al. 2012

Gastroenterology Research and Practice

View full text Add to dashboard Cite

This paper reviews the literature about first-line therapies for H. pylori infection in recent years. First-line therapies are facing a challenge because of increasing treatment failure due to elevated antibiotics resistance. Several new treatment strategies that recently emerged to overcome antibiotic resistance have been surveyed. Alternative first-line therapies include bismuth-containing quadruple therapy, sequential therapy, concomitant therapy, and hybrid therapy. Levofloxacin-based therapy shows impressive efficacy but might be employed as rescue treatment due to rapidly raising resistance. Rifabutin-based therapy is also regarded as a rescue therapy. Several factors including antibiotics resistance, patient compliance, and CYP 2C19 genotypes could influence the outcome. Clinicians should use antibiotics according to local reports. It is recommended that triple therapy should not be used in areas with high clarithromycin resistance or dual clarithromycin and metronidazole resistance.

show abstract

Comparison of the once-daily levofloxacin-containing triple therapy with the twice-daily standard triple therapy for first-lineHelicobacter pylorieradication: a prospective randomised study

Cited by 15 publications

References 23 publications

Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin

Assessment of Helicobacter pylori eradication rate of triple combination therapy containing levofloxacin

Review: Clinical Management of Helicobacter pylori Infection in China

The Optimal First-Line Therapy ofHelicobacter pyloriInfection in Year 2012

Contact Info

Product

Resources

About